Citations 1
A Clinical Case of Treatment-Emergent Acinetobacter baumannii Non-Susceptibility to Sulbactam-Durlobactam
Sharara, Sima L. , Diaz, Lorena, Asempa, Tomefa E, Martinez, Jose R W, Canales, Nicolas, Bergman, Yehudit , Murphy, Shannon G. , Karaba, Sara M. , Clark, Andrew E. , Zurawski, Daniel V, Cosgrove, Sara E, Simner, Patricia J, Munita, José M. , Tamma, Pranita D. , Tamma, Pranita D , Clark, Andrew E. , Karaba, Sara M , Bergman, Yehudit , Munita, Jose M , Sharara, Sima L. , Díaz, Lorena , Asempa, Tomefa E. , Canales, Nicolás, Murphy, Shannon G. , Zurawski, Daniel V. , Cosgrove, Sara E. , Simner, Patricia J.
Clinical Infectious Diseases | July 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract We report an eightfold increase in sulbactam-durlobactam MICs in a carbapenem-resistant Acinetobacter baumannii cerebrospinal fluid isolate recovered after 14 days of sulbactam-durlobactam plus meropenem therapy. Treatment-emergent mutations in the AdeFGH efflux system were identified, accompanied by a 166-fold increase in adeG expression. Efflux pump inhibition restored sulbactam-durlobactam susceptibility.